Your browser doesn't support javascript.
loading
Fetal allotransplant recipients are resistant to graft-versus-host disease.
Riley, John S; McClain, Lauren E; Stratigis, John D; Coons, Barbara E; Bose, Sourav K; Dave, Apeksha; White, Brandon M; Li, Haiying; Loukogeorgakis, Stavros P; Fachin, Camila G; Dias, Andre I B S; Flake, Alan W; Peranteau, William H.
Afiliação
  • Riley JS; Center for Fetal Research, The Children's Hospital of Philadelphia, Philadelphia, PA.
  • McClain LE; Center for Fetal Research, The Children's Hospital of Philadelphia, Philadelphia, PA.
  • Stratigis JD; Center for Fetal Research, The Children's Hospital of Philadelphia, Philadelphia, PA.
  • Coons BE; Center for Fetal Research, The Children's Hospital of Philadelphia, Philadelphia, PA.
  • Bose SK; Center for Fetal Research, The Children's Hospital of Philadelphia, Philadelphia, PA.
  • Dave A; Center for Fetal Research, The Children's Hospital of Philadelphia, Philadelphia, PA.
  • White BM; Center for Fetal Research, The Children's Hospital of Philadelphia, Philadelphia, PA.
  • Li H; Center for Fetal Research, The Children's Hospital of Philadelphia, Philadelphia, PA.
  • Loukogeorgakis SP; Center for Fetal Research, The Children's Hospital of Philadelphia, Philadelphia, PA.
  • Fachin CG; Center for Fetal Research, The Children's Hospital of Philadelphia, Philadelphia, PA.
  • Dias AIBS; Center for Fetal Research, The Children's Hospital of Philadelphia, Philadelphia, PA.
  • Flake AW; Center for Fetal Research, The Children's Hospital of Philadelphia, Philadelphia, PA.
  • Peranteau WH; Center for Fetal Research, The Children's Hospital of Philadelphia, Philadelphia, PA. Electronic address: peranteauw@chop.edu.
Exp Hematol ; 118: 31-39.e3, 2023 02.
Article em En | MEDLINE | ID: mdl-36535408
In utero hematopoietic cell transplantation (IUHCT) is an experimental treatment for congenital hemoglobinopathies, including Sickle cell disease and thalassemias. One of the principal advantages of IUHCT is the predisposition of the developing fetus toward immunologic tolerance. This allows for engraftment across immune barriers without immunosuppression and, potentially, decreased susceptibility to graft-versus-host disease (GVHD). We demonstrate fetal resistance to GVHD following T cell-replete allogeneic hematopoietic cell transplantation compared with the neonate. We show that this resistance is associated with elevated fetal serum interleukin-10 conducive to the induction of regulatory T cells (Tregs). Finally, we demonstrate that the adoptive transfer of Tregs from IUHCT recipients to neonates uniformly prevents GVHD, recapitulating the predisposition to tolerance observed after fetal allotransplantation. These findings demonstrate fetal resistance to GVHD following hematopoietic cell transplantation and elucidate Tregs as important contributors.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Doença Enxerto-Hospedeiro Limite: Humans / Newborn Idioma: En Revista: Exp Hematol Ano de publicação: 2023 Tipo de documento: Article País de publicação: Holanda
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Doença Enxerto-Hospedeiro Limite: Humans / Newborn Idioma: En Revista: Exp Hematol Ano de publicação: 2023 Tipo de documento: Article País de publicação: Holanda